Integra Lifesciences Holdings (IART) EBITDA (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of EBITDA data on file, last reported at $11.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 174.01% year-over-year to $11.5 million; the trailing twelve-month figure through Mar 2026 stood at -$466.4 million (down 5310.62% YoY), and the FY2025 full-year result was -$493.4 million, down 1836.55% from the prior year.
• EBITDA retreated to $11.5 million in Q1 2026, from $23.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $67.8 million in Q4 2022 to a low of -$512.7 million in Q2 2025.
• A 5-year average of -$6.1 million and a median of $23.0 million in 2025 frame the typical range for EBITDA.
• Peak annual rise in EBITDA reached 244.31% in 2025, while the deepest fall reached 16825.52% in 2025.
• Tracing IART's EBITDA over 5 years: stood at $67.8 million in 2022, then plunged by 46.86% to $36.0 million in 2023, then retreated by 1.17% to $35.6 million in 2024, then tumbled by 35.33% to $23.0 million in 2025, then slumped by 50.22% to $11.5 million in 2026.
• Business Quant data shows IART's EBITDA at $11.5 million in Q1 2026, $23.0 million in Q4 2025, and $11.8 million in Q3 2025.